Page 12 - Skye Bioscience News Today

Pfizer's chief development officer, Rod MacKenzie, is the Big Pharma's second executive to retire in early 2022. NIH Director Francis Collins will also hit the exit, before the end of this year. Sanofi poaches Gilead cancer executive Valeria Fantin to run its oncology research.

Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. From the first research of tetrahydrocannabinol(THC) in 1964 by Raphael Mechoulam to the recent findings of the hundreds of cannabinoids that can alleviate symptoms of a plethora of illnesses and diseases, we now kn...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, ... Skye Bioscience, Inc.March 8, 2021 GMT San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases...

The following article is sponsored by Skye Bioscience, Inc. The information contained in this article in no way represents investment advice or opinion on ...